Helicobacter pylori treatment and antibiotic susceptibility: Results of a five-year audit

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 4, 1999, Pages 512-516

  Fraser, A G ^a   Moore, L ^b   Hackett, M ^b   Hollis, B ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

Antibiotics; Clarithromycin; Helicobacter pylori; Metronidazole

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIULCER AGENT; BISMUTH CITRATE; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; RANITIDINE; TETRACYCLINE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CHILD; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; TREATMENT OUTCOME;

EID: 0032883297     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1999.tb00752.x     Document Type: Article

References (25)

1. 1. Lam SK, Talley NJ. Helicobacter consensus. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12.
2. 2. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-43.
3. 3. Fraser AG, Scragg R, Metcalf P, McCullough S, Yeates NJ. Prevalence of Helicobacter pylori in different ethnic groups in New Zealand children and adults. Aust NZ J Med 1996; 26: 646-51.
4. 4. Megraud F, Doermann HP. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 1998; 43 (Suppl. 1): S61-S65.
5. 5. Lee A, Hazell S. Antimicrobial resistance and Helicobacter pylori: impacts on current and future therapies [editorial]. Aust NZ J Med 1998; 28: 3-4, 17.
6. 6. Fraser AG, Moore L, Ali MR, Hollis B, Little SV. An audit of low dose triple therapy for eradication of Helicobacter pylori. NZ Med J 1996; 109: 290-2.
7. 7. Cutler AF, Havstad S, Ma CK et al. Accuracy of invasive and non-invasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995; 109: 313-5.
8. 8. Fraser AG, Schreuder V, Chua L, Moore L. Follow-up after successful eradication of H. pylori - symptoms and re-infection. J Gastro Hepatol 1998; 13: 555-9.
9. 9. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-27.
10. 10. Forbes GM, Collins BJ, McCullough CA, Coombs GW, Robins PD. Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance. Aust NZ J Med 1998; 28: 13-7.
11. 11. Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 823-7.
12. 12. Banatvala N, Davies GR, Abdi Y, Clements L, Rampton DS, Hardie JM, Feldman RA. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut 1994; 35: 1562-6.
13. 13. Ching CK, Leung KP, Yung RWH et al. Prevalence of metronidazole resistant Helicobacter pylori strains among the Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut 1996; 38: 675-8.
14. 14. Morton D, Bardhan KD. Antimicrobial resistance in Helicobacter pylori clinical isolates - An age-old or an old-age enigma? Gut 1999; 44 (Suppl. 1): A69 (Abstr.).
15. 15. Morton D, Bardhan KD. A six year assessment of tinidazole, metronidazole, clarithromycin, tetracycline, and amoxycillin resistance in Helicobacter pylori clinical isolates - a rising tide of antibiotic resistance? Gut 1998; 42 (Suppl.): A78 (Abstr.).
16. 16. Van der Wouden EJ, van Zwet AA, Vosmaer GD, Oom JA, de-Jong A, Kleibeuker JH. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. Emerg Infect Dis 1997; 3: 385-9.
17. 17. Ling TK, Cheng AF, Sung JJ, Yiu PY, Chung SS. An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study. Helicobacter 1996; 1: 57-61.
18. 18. Midolo PD, Lambert JR, Turnidge JD. Metronidazole resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy. J Gastroenterol Hepatol 1996; 11: 290-2.
19. 19. Midolo PD, Bell JM, Lambert JR, Turnidge JD, Grayson ML. Antimicrobial resistance testing of Helicobacter pylori: a comparison of E-test and disk diffusion methods. Pathology 1997; 29: 411-4.
20. 20. Xia HX, Buckley M, Keane CT, O'Morain CA. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 1996; 37: 473-81.
21. 21. Glupczynski Y, Burette A, Lamy V, Garrino MG. Evolution of H. pylori primary resistance to antimicrobial agents in Belgium between 1995 and 1998. Gut 1998; 43 (Suppl. 2): A48 (Abstr.).
22. 22. Xia H, Keane CT, Beattie S, O'Morain CA. Standardization of disk diffusion and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 1994; 38: 2357-61.
23. 23. Henriksen TH, Brorson O, Schoyen R, Thoresen T, Lia A. A simple method for determining metronidazole resistance of Helicobacter pylori. J Clin Microbiol 1997; 35: 1424-6.
24. 24. Glupczynski Y, Andersen LP, Lopez-Brea M, Megraud F. Towards standardisation of antimicrobial susceptibility testing of H. pylori: preliminary results of a European multicentre study group. Gut 1998; 43 (Suppl. 2): A47 (Abstr.).
25. 25. Katelaris PH, Lambert J, Davidson G, Yeomans N, for the HERO Study Group. A randomised double blind multicentre study of omeprazole and metronidazole with either amoxycillinor clarithromycin for the eradication of H. pylori in patients with duodenal ulcer - the HERO study. J Gastroenterol Hepatol 1998; 13 (Suppl.): A111 (Abstr.).